M.R. García-Campelo

Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal et al. · Journal of Clinical Oncology · 2022 · 322 citations · Full text

Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy‐induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials

Renata Ferrarotto, Ian C. Anderson, Balazs Medgyasszay et al. · Cancer Medicine · 2021 · 48 citations · Full text

Two biomarker-directed randomized trials in European and Chinese patients with nonsmall-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies

Teresa Morán, Jia Wei, Manuel Cobo et al. · Annals of Oncology · 2014 · 30 citations · Full text

Oncology, Medicine, Pathology +10

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)

Rafael Rosell, B. Massuti Sureda, Carlota Costa et al. · Annals of Oncology · 2012 · 17 citations

Overall Survival, Medicine, Egfr L858r +9

LBA15 Amivantamab plus chemotherapy (with or without lazertinib) vs chemotherapy in EGFR-mutated advanced NSCLC after progression on osimertinib: MARIPOSA-2, a phase III, global, randomized, controlled trial

Antonio Passaro, Byoung Chul Cho, Yan Wang et al. · Annals of Oncology · 2023 · 16 citations · Full text

Oncology, Medicine, Phase Iii +7